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The clinical management of COVID-19 is a rapidly evolving field 
that has challenged clinicians across the world. Initially described 
as ‘just like flu’, we have come to appreciate marked differences and 
new challenges in managing this severe pneumonia, its complications 
and extrapulmonary manifestations. Groote Schuur Hospital (GSH) 
is the 950-bed academic teaching hospital of the University of Cape 
Town, located at the epicentre of South Africa (SA)’s COVID-19 
epidemic in its first 4 months. As of 6 August 2020, we had admitted 
3 487 persons under investigation (PUIs), and 1 781 COVID-19 cases 
have been confirmed (Western Cape Provincial Health Data Centre, 
unpublished). In this article, we share our experiences of developing a 
clinical service for COVID-19 in a tertiary centre in SA, and focus on 
new developments and areas of contention in clinical management of 
COVID-19 as well as practices implemented in our hospital. 
This open-access article is distributed under 
Creative Commons licence CC-BY-NC 4.0.
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The SARS-CoV-2 pandemic has presented clinicians with an enormous challenge in managing a respiratory virus that is not only capable 
of causing severe pneumonia and acute respiratory distress syndrome, but also multisystem disease. The extraordinary pace of clinical 
research, and particularly the surge in adaptive trials of new and repurposed treatments, have provided rapid answers to questions 
of whether such treatments work, and has resulted in corticosteroids taking centre stage in the management of hospitalised patients 
requiring oxygen support. Some treatment modalities, such as the role of anticoagulation to prevent and treat potential thromboembolic 
complications, remain controversial, as does the use of high-level oxygen support, outside of an intensive care unit setting. In this article, we 
describe the clinical management of COVID-19 patients admitted to Groote Schuur Hospital, a major tertiary level hospital at the epicentre 
of South Africa’s SARS-CoV-2 epidemic during its first 4 months. 
S Afr Med J 2020;110(10):973-981. https://doi.org/10.7196/SAMJ.2020.v110i10.15157
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Oxygen support outside of the ICU 
About 20% of hospitalised patients with confirmed SARS-CoV-2 
pneumonia will develop acute respiratory distress syndrome, and ~12% 
will meet conventional indications for intubation and mechanical 
ventilation.[1,2] In SA, the capacity to treat forecasted numbers of 
patients with acute hypoxaemic respiratory failure (AHRF) with 
ventilation in the intensive care unit (ICU) is severely constrained.[3] 
Furthermore, mechanical ventilation for COVID-19-associated AHRF 
is associated with variable, but often very high, mortality.[1] There has 
been considerable interest in strategies that improve oxygenation non-
invasively, and that could be deployed in the non-ICU setting. High-
flow nasal cannula (HFNC) is an oxygen delivery method capable of 
supplying high inspired partial pressures of warmed and humidified 
oxygen, while reducing anatomic dead space, work of breathing and 
respiratory rate, and increasing positive pressure and compliance. 
The device consists of a flow generator providing gas flow rates up 
to 60 L/min, an air-oxygen blender and a humidifier that saturates 
the gas mixture, markedly improving patient comfort, tolerance and 
compliance.[4] 
In the non-COVID-19 setting, HFNC has been shown to avoid 
intubation compared with conventional oxygen supply devices,[5,6] 
and there are data to suggest that it may be useful in patients 
with COVID-19 pneumonia.[7-9] At GSH, in anticipation of severe 
pressure on ICU beds, we cohorted patients with laboratory-
confirmed or highly suspected COVID-19 pneumonia and severe 
respiratory failure (ratio of arterial partial pressure of oxygen and 
fraction of inspired oxygen typically <100) in non-critical medical 
wards and treated them with HFNC and awake self-proning as 
a pre-ICU intervention. Despite the necessary compromises in 
offering this therapy in a less-monitored setting with a higher 
patient-to-nurse ratio as compared with ICU, we have found it to 
be a feasible strategy with lower overall intubation rates, less ICU 
resource utilisation and cost savings. HFNO may be considered 
as an appropriate mode of respiratory support where access to 
the infrastructure and/or expertise of ICU care is limited or, 
secondly, transport of clinically unstable patients to a facility with a 
designated ICU is potentially hazardous and undesirable. The two 
main disadvantages of HFNC relate to the risk of aerosolisation 
and the adequacy of oxygen supplies. Concerns about the former 
have not been substantiated,[10,11] but appropriate precautions (full 
personal protective equipment (PPE) including N95 respirator) 
should still apply. However, the scaling of any HFNC requires input 
from engineers and ongoing monitoring of local capacity and the 
oxygen supply chain. Based on our collective experiences, we have 
identified a number of important dos and don’ts relating to HFNC 
use for COVID-19 (Table 1).
The value of a dedicated intubation 
team
Early planning for the dramatic increased intubation requirement is 
critical, particularly in view of the high risk to staff from this aerosol-
generating procedure (AGP). As routine and elective surgery 
de-escalated, the Department of Anaesthesia and Perioperative 
Medicine redeployed approximately half of its consultants and 
registrars to COVID-19 services and formed a dedicated COVID-19 
Anaesthesia and Airway Team. We created a highly protocolised 
approach to safe intubation, which defined roles, checklists and 
systems (https://www.sasaCOVID19.com). We used our experience 
in simulation to provide open training sessions for all staff in 
appropriate use of PPE for AGPs, rapid intubation and patient 
transfers. We undertook in situ simulation in theatres, emergency 
departments and wards, and actively encouraged cross-disciplinary 
participation of staff in interchangeable roles. This strengthened 
interdepartmental collaboration and allowed systems testing and 
rapid improvement prior to the patient surge.
To date, the COVID-19 Anaesthesia and Airway Team have 
completed over 400 cases, including intubations for respiratory 
failure (particularly failure of high-flow nasal oxygen), anaesthesia 
for surgery, ICU tracheostomies and trauma/emergency intubations, 
in PUIs or COVID-19 patients, without any infections documented 
within our team. The use of reusable respirators with filters 
(allowing daily cleaning) by the team has practically eliminated the 
demand for the approximately 50 disposable N95 respirators that 
would have otherwise been required per day. 
To counteract the exceptionally rapid and profound oxygen 
desaturation and the physical limitations of PPE, we adopted 
universal video laryngoscopy and routine use of tracheal tube 
introducers using a standardised technique.[12] This has maintained 
a rapid and high first-pass intubation success rate. Other pertinent 
lessons include the need for pre-induction fluid loading in patients 
who are often dehydrated to the point of hypovolaemia due to 
enhanced insensible fluid loss from high respiratory rates on oxygen 
for several days, and frequent need for induction dose adjustment 
and boluses of inotropes to support the transition to positive 
pressure ventilation. However, the greatest gains of instituting a 
COVID-19 intubation service have been breaking down silos of care, 
cross-discipline integrated training, systems strengthening through 
recursive testing of protocols and standardisation, and bridging the 
Table 1. The dos and don’ts of delivering oxygen via HFNC
Dos Don’ts
• Ensure proper sizing, fitting and securement of nasal cannulae
• Have patients wear a surgical mask over the HFNC to minimise 
risk of bioaerosolisation
• Monitor patients with continuous pulse oximetry and observe 
closely for any malposition or displacement of nasal interface
• Allow patients to eat and drink while on HFNC
• Combine HFNC with awake self-proning to improve 
oxygenation
• To treat severe hypoxia, do not persist with conventional nasal cannulae at 
high flow rates (>6 L/min) or ‘double oxygen’ – rather use HFNC if available
• If mechanical ventilation is an option, do not consider HFNC as first-line 
in hypercapnic, haemodynamically unstable or obtunded patients or those 
with imminent respiratory arrest
• Do not initiate HFNC without regular clinical assessments of its efficacy 
(especially during the first few hours of treatment)
• Do not delay intubation if there is a decline on HFNC (consistent or rapid 
increase in respiratory rate, consistently or rapidly declining SpO2, or 
exhaustion)
• Do not offer a scalable HFNC service without first consulting with engineers 
about local oxygen capacity
HFNC = high-flow nasal cannula.
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safe transfer of patients from the emergency department or wards 
to the ICU. 
Antimicrobial stewardship 
At the time of writing, no single antimicrobial has been shown to 
reduce mortality from SARS-CoV-2 infection. The broad-acting 
antiviral remdesivir has been shown to reduce duration of illness, 
but not directly affect mortality.[13] Results from larger randomised 
controlled trials are awaited. Despite being much vaunted, 
hydroxychloroquine has been shown to have no beneficial effect, and 
has been observed to trend towards worse outcomes in hospitalised 
patients.[14] The antiretroviral combination of lopinavir/ritonavir also 
showed no benefit.[15] 
The existing epidemic of antibiotic-resistant bacterial infections 
in SA has been one of many entrenched public health crises, such 
as diabetes and obesity, to collide with COVID-19. The primary 
driver of antibiotic resistance is antibiotic consumption, historically 
fuelled by inappropriate prescribing for respiratory viral infections. 
Influenza pandemics characterised by bacterial co-infections begged 
the question of an equal impact from SARS-CoV-2. However, pooled 
prevalence of laboratory-confirmed bacterial infections was 7% 
throughout the course of hospitalisation in the largest systematic 
review and meta-analysis conducted to date.[16] Bacterial coinfection 
at the time of presentation to hospital is likely much lower. Despite 
this extremely low level, between 56 and 95% of patients in these and 
other studies received empirical antibiotics.[17] 
Our approach is to withhold antibiotics in patients with a clinical 
or laboratory-confirmed diagnosis of COVID-19, and stop antibiotics 
in those treated empirically, even though clinical and radiological 
differentiation from bacterial pneumonia is difficult. Biomarkers are 
unhelpful in optimising antibiotic use in COVID-19, as high levels 
of C-reactive protein (CRP) are common, and no good data exist for 
procalcitonin (PCT), despite it being an indicator of severity, with a 
5-fold increase in odd ratio of severe COVID-19 if PCT is raised.[18] 
We do not advocate measuring CRP or PCT as biomarkers for 
COVID-19 infection.
For patients who deteriorate during their hospital stay, hospital-
acquired infection (HAI) should always be considered. HAIs 
are predominantly seen in ICU patients, and may be multi-drug 
resistant, especially when selected out by empirical broad-spectrum 
antibiotics used earlier. Empirical antibiotic choice will depend on 
local resistance patterns. If antibiotics are to be given, blood and 
site-directed specimens should be sent for culture prior to starting 
antibiotics, and the first dose should not be delayed. Oral medications 
should always be used in preference to intravenous whenever possible 
to reduce venous catheter-associated infections. 
Corticosteroids
To date, only the anti-inflammatory therapy of 6 mg IV or oral 
dexamethasone daily for 10 days has been shown to reduce mortality in 
COVID-19 patients requiring oxygen – the largest gains were observed 
in those who were mechanically ventilated, with one-third reduction 
in death at 28 days v. one-fifth reduction in non-ventilated hospitalised 
patients requiring any level of oxygen support.[19] There was no 
benefit in patients not requiring oxygen support. We use intravenous 
dexamethasone in ventilated patients and, wherever possible, 40 mg 
oral prednisolone to negate the need for a venous catheter.
Anticoagulation 
International cohorts report the incidence of confirmed venous 
thromboembolism (VTE) as between 20 and 60% among critically 
ill COVID-19 patients,[20,21] and >5% (up to 22% in one cohort) 
in those less severely hypoxic, despite heparin prophylaxis,[22-24] 
much higher rates than general medical patients.[25,26] Even in the 
absence of overt VTE, microvascular thrombosis in the pulmonary 
circulation may also contribute to hypoxaemic respiratory failure 
in COVID-19.[27] 
The recognition and diagnosis of VTE is more challenging 
in the context of COVID-19: patients with severe COVID-19 
pneumonia often have fluctuating oxygen requirements that may 
mask a new thrombotic event; they may be too unstable for transfer 
to undergo investigation; and IPC concerns may restrict access to 
diagnostic testing. We follow international guidelines to not screen 
routinely for VTE with lower-limb Doppler ultrasound or computed 
tomography pulmonary angiography.[21,28] Our indications for testing 
are clinically guided and include suspected symptomatic lower limb 
deep vein thrombosis, sudden unexplained respiratory deterioration 
and persistent or refractory hypoxia. We have recognised VTE across 
this clinical spectrum in our COVID-19 service. 
All inpatients with suspected or confirmed COVID-19 pneumonia 
receive VTE prophylaxis unless there is a contraindication. Low-
molecular-weight heparin is preferred due to ease of use (subcutaneous 
injection), predictable pharmacokinetics and limited monitoring 
requirements. Our practice has recently changed to provide enhanced 
or ‘intermediate’ dose enoxaparin prophylaxis for patients with 
hypoxic pneumonia (Table 2). This is to overcome putative heparin 
resistance[29] in COVID-19 due to increased circulating fibrinogen, 
factor VII and von Willebrand factor levels.[30,31] We have also 
witnessed incident VTE despite standard heparin prophylaxis,[20] and 
intermediate dose enoxaparin may ensure better protection for obese 
patients who may be underdosed because of failure to do accurate 
weight-based dosing. The intermediate dosing strategy is based on 
expert opinion and does not comply with current national guidance, 
which recommends the use of standard dose heparin prophylaxis in 
COVID-19; however, several international hospital groups[32] have 
instituted this practice, and a there is support in published consensus 
documents by major international societies.[28,32,33] Major bleeding 
events appear to be uncommon with anticoagulant use in COVID-
19, but a recent retrospective study from Italy reported substantially 
increased bleeding risk with high doses of heparin in a cohort with a 
median age of 71 years.[34] Therefore, we are cautious with using non-
standard-dose heparin prophylaxis in patients >70 years and those 
who have other bleeding risk factors.
D-dimer elevation[35,36] and obesity[37,38] are both common in severe 
COVID-19, and independently correlate with increased VTE risk and 
with mortality. Retrospective studies suggest improved survival for 
Table 2. Enoxaparin dosing for VTE prophylaxis
Total body weight (kg) Dose (subcutaneous) Renal impairment  (eGFR <30 mL/min)
<80 1 mg/kg daily Reduce total daily dose by 50%
80 - 100
0.5 mg/kg 12-hourly Reduce to once-daily dosing
>100
eGFR = estimated glomerular filtration rate.
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therapeutic anticoagulation in critically ill 
patients requiring mechanical ventilation[39] 
and those with very high D-dimer levels. [40] 
Because of greatly increased VTE risk in 
these groups (particularly in our population 
with a high prevalence of obesity) and limited 
diagnostic testing, we empirically prescribe 
therapeutic anticoagulation (Table 3) for 
the following patients in our service: those 
requiring high flow nasal cannula oxygen 
or mechanical ventilation (considered to 
be critically ill); D-dimer levels >1.5 × 
upper limit of normal or rising on serial 
measurement; and those with clinically 
suspected VTE. Major bleeding events 
appear to be uncommon with anticoagulant 
use in COVID-19, but we are cautious with 
this approach in patients older than 75 years 
and those who have other bleeding risk 
factors.
Arterial thrombosis occurs much 
less frequently than VTE,[41] but we have 
seen major events including critical 
limb ischaemia, thrombosis of the aorta, 
mesenteric and femoral arteries and several 
patients complicating with stroke and 
myocardial infarction. Prophylaxis with anti-
platelet agents is not recommended and is 
not part of our practice.
Diabetes stewardship
The association between diabetes and 
in creased morbidity and mortality from 
COVID-19 has been well described 
globally. [1,42,43] We have seen large numbers 
of people living with diabetes (PLWD) and 
diagnosed with COVID-19 admitted with 
severe disease and/or diabetic ketoacidosis 
(DKA), as well as a large number of people 
diagnosed with COVID-19 presenting with 
new onset diabetes or first-time DKA.  
To enable practical and consistent 
in patient management of diabetes and 
COVID-19, we disseminated protocols for 
achieving glycaemic control and managing 
DKA in these patients (Fig. 1). The use of a 
single diabetes monitoring chart that included 
advice on the prescription and titration 
of insulin as well as the management of 
hypoglycaemia allowed for a unified approach 
in managing hyper- and hypoglycaemia.  
Despite these measures, inpatient manage-
ment of PLWD diagnosed with COVID-19 
proved challenging. Deployment of doctors 
and nurses inexperienced in diabetic 
management was a challenge and required 
rapid upskilling. Optimal inpatient glycaemic 
control requires frequent fingerprick glucose 
monitoring and injection of insulin, thereby 
increasing exposure of HCWs to infectious 
patients. To combat this, we encouraged the 
use of simple treatment regimens requiring 
less exposure, whenever clinically possible.  
To simplify management on discharge, 
training was given to the patient on 
Table 3. Enoxaparin dosing for therapeutic anticoagulation
Total body weight (kg) Dose (subcutaneous) Renal impairment (eGFR <30 mL/min)
<100 1 mg/kg 12-hourly
Reduce to once-daily dosing100 - 150 1 mg/kg 12-hourly; up to 150 mg 12-hourly*
>150 0.75 mg/kg 12-hourly*
eGFR = estimated glomerular filtration rate. 
*Suggest anti-Xa monitoring (if available) for doses >120 mg 12-hourly.
 Division of Endocrinology, Groote Schuur Hospital  08 May 2020 
Glucose 
target 
less than 10 
mmol/L 
avoid level < 5 
mmol/L 
In-hospital management of diabetes in patients with SARS-CoV-2 infection 
 
Problems 
1. Patients living with diabetes have an increased risk of morbidity and mortality from infection with 
SARS-Cov-2 
2. Poorly-controlled diabetes is a risk factor for increased morbidity and mortality from SARS-CoV-2 
infection 
3. Data from an observational study to show that morbidity and mortality from SARS-CoV-2 infection 
may be improved with better diabetes control 
4. Acute hyperglycaemia has been shown to upregulate ACE2 expression on cells which might 
facilitate viral cell entry 
5. In-hospital hypoglycaemia increases morbidity and mortality   
6. Patients with diabetes and severe COVID-19 have marked insulin resistance disproportionate to 
the critical illness caused by other conditions and this may require very high doses of insulin to 
maintain euglycaemia 
7. Good diabetes control in the hospital requires frequent fingerprick blood glucose testing (at least 
before each meal and at 22h00) and administration of insulin thereby increasing exposure of 
healthcare workers to the infected patient 
8. There are no robust studies to guide the in-patient management of diabetes in patients with diabetes 
that are infected with SARS-CoV-2 
9. Limited time available to stabilise on longterm treatment regimens and, at the moment, limited 
options for outpatient follow-up  
 
Recommendations 
1. HbA1c measurement on admission (unless HbA1c available within past 1 month) 
2. INITIAL management of diabetes will depend on the HbA1c and disease severity 
a. HbA1c < 9% plus mild disease (no pneumonia or mild pneumonia with respiratory rate < 30 
breaths/min and O2 saturation ≥ 94%)  
• continue pre-admission medication 
o stop metformin if eGFR<45 ml/min 
o stop sulphonylureas (glimepiride, glibenclamide) if eGFR<90 ml/min 
o stop SGLT2 inhibitors 
b. HbA1c < 9% plus severe disease (respiratory rate > 30 breaths/min and/or O2 saturation < 
94%) OR HbA1c > 9% with any severity of illness 
• Stop all oral diabetes medications 
• Continue with pre-admission insulin regimen OR commence insulin as per Diabetes 
Chart, preferably using a basal bolus regimen 
• Use insulin correction doses as per Diabetes Chart 
c. Patients may have other reasons (another infection, on steroids, etc) apart from 
COVID-19 that may change your INITIAL management so good and usual clinical 
judgement is required at all times 
d. Encourage self-monitoring of fingerprick blood glucose by the patient if clinical status allows  
e. Encourage self-administration of insulin by the patient if clinical status allows  
f. Monitor fingerprick glucose twice daily if on oral therapy and 4 times daily if on insulin  
g. Review glycaemic control and management daily 
h. Aim for a fingerpick blood glucose between 5.0 mmol/L to 10 mmol/L at all times but 
preferably closer to 8.0 mmol/L 
i. Very important to avoid hypoglycaemia (glucose <4.0 mmol/L) and manage hypoglycaemia 
as per Diabetes Chart 
j. Nursing staff and doctors must please regularly educate patients on monitoring of 
fingerprick blood glucose, injection technique and diet, especially those with newly-
diagnosed diabetes 
k. Important to review the long-term management regimen prior to discharge 
l. All patients with diabetes must please be given an appointment to attend the GSH Diabetes 
Clinic 1 month after discharge from hospital or 1 month after their self-isolation ends (please 
contact the Endo-on-call who will immediately give an appointment) 
Fig. 1. In-hospital management of diabetes in patients with COVID-19. (eGFR = estimated glomerular 
filtration rate.)
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fingerprick glucose monitoring and the 
administration of insulin, and a handout 
was provided describing basic dietary advice 
as well as glycaemic management princi-
ples, including insulin correction doses 
and glucose targets (Fig. 2). Furthermore, 
a telephonic helpline was established for 
the patient to contact should (s)he require 
guidance.
Mental health – 
supporting staff and 
patients alike 
Many HCWs have reported that mental 
health conditions linked to their work 
have been made worse by the COVID-19 
epidemic. Working long hours in unfamiliar 
settings and in PPE, fear of contracting 
SARS-CoV-2 and passing it to their loved 
ones, seeing many patients die and breaking 
bad news to bereaved families are all having 
an impact on wellbeing. At the same time, 
the lockdown has meant that many have 
been unable to recharge their batteries. 
There is no socialising, and some have 
isolated themselves from their families to 
protect them. 
Working closely in an established 
partnership between our hospital and 
Metropolitan Health, we developed a GSH 
Wellness Team to prioritise employee health 
and wellness during the crisis. We support 
on-site individual and group counselling 
to provide a containing and supportive 
space wherein HCWs are able to share their 
anxieties and fears and the traumas that they 
have experienced within the hospital context 
as a result of severe patient morbidity and 
mortality.   
We perform daily mental health ward 
rounds to screen for patients who require 
mental health assessment, management and 
treatment. Common reasons for referral 
are agitated delirium (Fig. 3), bereavement, 
anxiety and behavioural problems. Smart-
phones have enabled us to FaceTime families 
within the high-risk COVID-19 wards to 
address the isolation and trauma that many 
patients experience. 
Palliative care for 
COVID-19 patients
The World Health Organization (WHO) 
strongly recommends that palliative care 
should be accessible in all institutions that 
provide care for persons with COVID-19.[44] 
The Palliative Care Practitioners Association 
of SA (PalPrac) has created clinical guide-
lines on palliative care management for 
COVID-19 in SA (Fig. 4),[45] and has been 
supported by the provincial operational guide 
for implementation, with provincial training 
and mentorship by PalPrac.[46] Despite this, 
misconceptions around palliative care remain, 
and the lack of awareness, training and 
dedicated staff has hampered the integration 
of palliative care into healthcare facilities. 
We strengthened the established team at 
GSH with family medicine registrars and 
by building strong relationships with the 
psychiatry, psychology, oncology and social 
work departments. Three main categories 
of patients are referred: firstly, the known 
palliative care patients whose care has been 
comprom ised in the time of COVID-19. 
Social isolation, complex advanced decision-
making and downscaling of community 
palliative care resources have led to 
intensified palliative care for these patients in 
the hospital setting. Secondly, known patients 
in the COVID-19 wards requiring palliative 
care for an existing condition that has been 
complicated by the infection. The third 
group are the end-of-life patients dying from 
COVID-19-related complications because 
they were not candidates for ventilation. 
Terminal agitation, dyspnoea and delirium are 
the main symptoms requiring management. 
Pre-bereavement and bereavement care with 
families are essential components of palliative 
care, and psychiatry, psychology, spiritual care 
and social work colleagues worked alongside 
Division of Endocrinology, Groote Schuur Hospital, June 2020 
 
Patients with COVID-19 and NEW Diabetes Mellitus 
Discharge process 
 
• Try and discharge patients on the simplest regimen that will keep their fingerprick blood 
glucose in the range 6.0-9.0 mmol/L 
• All patients admitted in diabetic ketoacidosis (DKA) must be discharged on insulin 
• Whilst the patient is in the ward the nursing staff and doctors should instruct the patient 
on fingerpick blood glucose monitoring and insulin administration 
• As much as possible encourage self-monitoring of fingerprick blood glucose and self-
administration of insulin 
• Dietary advice: dietician, GSH Diabetes Stewardship dietary handout, COVID Ward 
handout 
• Before discharge please ensure that the following have been entered into the patient’s 
notes: HbA1c, weight, height, mid-upper-arm circumference 
• Patients on a basal bolus regimen 
o A few days before discharge review the need for this regimen and the ability of 
the patient to comply with this regimen, it is an intense regimen and many 
patients are unable to comply 
o To convert to a more simple regimen using a pre-mix insulin (such as 
Actraphane or Humulin 30/70) twice-daily follow these steps: 
▪ Work out the total amount of insulin per day that the patient is needing 
(i.e., the total daily dose, TDD) 
▪ Give two-thirds of the TDD before breakfast and one-third of the TDD 
before supper  
• Patients must monitor their fingerpick blood glucose before giving insulin and must use 






• After discharge patients can phone the Help Line, weekdays between 09h00 and 
13h00 to discuss any problems with a doctor 
• Patients must be please given an appointment for the GSH Diabetes Clinic for 2 weeks 
after the end of the patient’s self-isolation (please contact the Endo SR-on-call for an 
appointment date, this is the only way of getting an appointment so please do it this 
way) 
















Less than 4.0 Eat and re-check blood glucose in 20 minutes 
4.1 to 4.9 Decrease the prescribed dose of insulin by 4 units 
5.0 to 8.5 Give the prescribed dose of insulin 
8.6 -12.0 Increase the prescribed dose of insulin by 2 units 
Greater than 12.1 Increase the prescribed dose of insulin by 4 units 
 
Fig. 2. Discharge process for diabetics with COVID-19.
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the palliative care team to broaden the reach 
for patients and their families.
Radiology services for 
COVID-19 
Chest radiography is the mainstay of imaging, 
and it was planned as a mobile service for all 
COVID-19 suspects and patients using the 
two-radiographer technique. High demand 
caused strain on the service; however, this 
was somewhat offset by clustering patients 
whenever possible. 
Within the Radiology Department 
one machine was a ‘designated COVID-
19 scanner’ wherever possible. Magnetic 
resonance (MR) and CT scanning is 
performed with two radiographers  in 
attendance; one remains clean in the 
console room, planning and executing 
the scan. The second wears full PPE and 
assists with positioning the patient in the 
room, remaining with the staff transporting 
the patient until the patient leaves the 
department. After every PUI or COVID-
19 patient, the room is deep-cleaned by 
the housekeeping team and allowed 
to stand empty for an hour to ventilate. 
Ventilation and air flow must be checked 
by engineers to ensure it is adequate. The 
risk of transmission from asymptomatic or 
incorrectly categorised patients was offset by 
consistent PPE and IPC protocols.  
We reserved the use of CT chest (high 
resolution CT and CT pulmonary angio-
graphy) for complications and for inpatients 
not improving on treatment. Indications for 
CT imaging have evolved, now including 
in some instances patients who are 
persistently reverse transcriptase polymerase 
chain reaction (RT-PCR)-negative with an 
abnormal chest X-ray. 
A COVID-19 radiology meeting (initially 
held daily, then weekly) has been critical for 
discussing diagnostic challenges in imaging 
of COVID-19 patients. 
Ensuring rapid 
turnaround times for 
SARS-CoV-2 diagnostic 
tests
Rapid turnaround time (TAT) for the SARS-
CoV-2 RT-PCR diagnostic test is a critical 
factor in the clinical management of COVID-
19 and triage through the hospital. Inpatient 
and HCW samples were prioritised from 
the start. Major challenges around supply 
chain management and a shortage of qualified 
staff for the shift system created a stressful 
environment and affected the quality and 
productivity of our virology laboratory 
service. 
While direct communication with the 
laboratory to expedite urgent samples may 
be tempting, this adds further work and 
pressure on the already strained system. 
Eventually, we identified three key factors 
that improved TAT of urgent hospital 
samples. Firstly, a separate testing stream 
was established where samples were 
marked with a clearly visible red dot on 
the outside of the sample bag. Secondly, we 
identified the main bottleneck in testing 
as the nucleic acid extraction process, and 
developed an alternative extraction-free 
method, overcoming reagent shortages and 
saving precious processing time. Finally, 
work volumes were reduced by establishing 
additional testing laboratories – at the 
Greenpoint National Health Laboratory 
Service that tested community screening 
samples, and later, research laboratories at 
the University of Cape Town, allowing us 
to focus on serving the hospital population, 
and ultimately to improve quality and 
sample TAT. 
Developing research as 
part of the COVID-19 
response 
Three broad priority areas for research 
were identified: Establishing a clinical 
and laboratory data repository; under-
Management of Agitated Delirium 
Non-pharmacological or environmental support strategies should be instituted 
wherever possible. These include co-ordinating nursing care, preventing sensory 
deprivation and disorientation, and maintaining competence. 
 
Pharmacological treatment should be directed first at the underlying cause (if known) 
and then at the relief of specific symptoms of delirium. 
 
General principles of delirium management 
ONLY USE ANTIPSYCHOTICS IF THE PATEINT IS DISTRESSED OR AGITATED 
• Keep the use of sedatives and antipsychotic medications to a minimum. 
• Use one drug at a time. 
• Tailor doses according to age, body size and degree of agitation. 
• Titrate doses to effect. 
• Use small doses regularly, rather than large doses less frequently. 
• Review at least every 24 hours. 
• Increase scheduled doses if regular ‘as needed’ doses are required after the 
initial 24-hour period. 




Use lower doses especially in patients who are elderly. Discontinue these 
medications as soon as possible. Attempt a trial of tapering the medication once 
symptoms are in control. Antipsychotics can be associated with adverse neurological 
effects such as extrapyramidal symptoms, neuroleptic malignant syndrome, and 
tardive dyskinesia. Longer term use is also associated with metabolic syndrome.  
 
Haloperidol-Considered first-line agent. No trial data has demonstrated superiority 
of other antipsychotics over haloperidol; however, care must be taken to monitor for 
extrapyramidal and cardiac adverse effects. Avoid in Lewy body dementia and 
Parkinson’s disease, Avoid intravenous use where possible. However, in the medical 
ICU setting, IV is often used with close continuous ECG monitoring 
 
1) Start with either Haloperidol po or Risperidone po 0.5mg 12-hourly.  Can 
increase to up to 0.5mg 6-hourly  
2) If poor response to Haloperidol or Risperidone OR if patient is VERY agitated 
try Olanzapine 2.5mg po 12 hourly. Can increase to up to 2.5mg 8-hourly  
 
Benzodiazepines- AVOID and stop if already in use  
Reserved for delirium resulting from seizures or withdrawal from alcohol or 
sedative hypnotics OR Terminal delirium. Benzodiazepines are preferred over 
neuroleptics for treatment of delirium resulting from alcohol or sedative hypnotic 
withdrawal. Use special precaution when using benzodiazepines because they may 
cause respiratory depression, especially in patients who are elderly, those with 
pulmonary problems, or debilitated patients. 
 
Terminal agitated Delirium  
Midazolam 2.5 mg subcutaneously and increase or provide continuously through a 
syringe driver. (See Palprac guidelines – Figure 5) 
Fig. 3. Management of agitated delirium in COVID-19 patients. (ICU = intensive care unit; 
IV = intravenous; ECG = electrocardiogram.)
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taking local studies to understand 
clinical epidemiology in our population 
and to directly inform our practice; and 
contributing data to global observational 
and trial protocols. Early in our epidemic, 
the Department of Medicine, with ethics 
approval, implemented a protocol for 
collection and storage of clinical data linked 
to electronic records systems, a virtual 
repository for all clinical samples obtained 
from all COVID-19-related research, and 
a governance structure developed by a 
Departmental COVID-19 Research Steering 
Committee, which evaluates requests from 
investigators to access the data under 
approved protocols. This aims to ensure that 
no single research group has ‘ownership’ 
over data from COVID-19 patients, and 
avoids duplication in informed consent, 
study procedures and data reporting. 
Local studies are focusing on main areas 
of clinical presentation and management, 
i.e. the COVID-19 and HIV interaction, 
impact of diabetes on clinical outcomes, use 
of HFNC oxygen, respiratory co-infections 
and optimising anticoagulation. Our 
hospital is also a participating centre for 
the WHO’s SOLIDARITY trial,[47] and the 
ICU contributes to the International Severe 
Acute Respiratory and Emerging Infection 
Consortium database.[48]
A guiding principle of our efforts is 
that research conduct should contribute 
directly to the clinical service and not place 
additional burdens on staff or PPE, and 
that study procedures should not increase 
transmission risk in the hospital, e.g. 
through the use of paper-based records or 
performance of AGPs. Close engagement 
with ethical and regulatory bodies for the 
institution of rapid review processes for 
COVID-19-related projects and oversight 
in this challenging research environment is 
highly recommended.
Conclusion 
Clinical management of COVID-19 improves 
with experience, and we now have a suite of 
interventions that we believe improve clinical 
outcomes (Fig. 5). Notable developments 
have been the use of corticosteroids, HFNC 
outside of the ICU, a dedicated intubation 
team to support management of these 
challenging patients, rigour in relation to 
antibiotic and diabetic stewardship and 
the provision of strong mental health and 
palliative care services to benefit distressed 
patients and staff. The challenge continues, 
with the only certainty being that we still 
have much more to learn. 
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UCT/GSH DEPARTMENTS OF MEDICINE & SURGERY 
COVID-19 ADMISSION APPROACH
Management of laboratory confirmed or clinically diagnosed case
1. Oxygen therapy, escalating according to need
1. Nasal cannulae (2-6 L/min)
2. Face mask 40% (6-8 L/min)
3. Reservoir mask (flow to fill reservoir bag)
4. High flow nasal oxygen
5. Refer to ICU for intubation and ventilation
2. Awake proning if sats < 90%
3. Dexamethasone 6mg IVI or Prednisone 40mg PO daily
4. Enoxaparin (provided no contra-indication)
1. 40mg SC daily for prophylaxis 
2. Enhanced prophylactic doses if hypoxic pneumonia
3. If requiring high intensity oxygen or D-dimer > 1.5 then 
1mg/kg 12 hourly (weigh patient if possible)
5. Lansoprazole 30mg daily or Omeprazole 20mg daily
6. Paracetamol 1 g 6 hourly. Escalate analgesia if needed.
7. Appropriate management of co-morbidities (especially diabetes: 
SC insulin if hyperglycaemic; IVI insulin infusion and fluids if DKA)
8.    No routine antibiotics
9.    For some patients institution of palliative care appropriate
Investigations
1. NP or mid-turbinate swab for 
SARS-CoV-2 (if high suspicion
& swab neg then sputum)
2. Blood glucose






9. If ischaemic chest pain 
then TropT and ECG
Clinically-diagnosed cases are patients 
with characteristic symptoms, positive contact
and/or characteristic CXR with bilateral 
ground glass infiltrates with prominent 
peripheral distribution
Version: 9 Aug 2020
Fig. 5. Groote Schuur Hospital (GSH)/University of Cape Town (UCT) approach to admissions with 
COVID-19. (ICU = intensive care unit; IVI = intravenous infusion; PO = per os; SC = subcutaneous; 
DKA = diabetic ketoacidosis; NP = nasopharyngeal; ABG = arterial blood gas; CUE = creatinine,  urea 
and electrolytes; TropT = troponin T; ECG = electrocardiogram; CXR = chest X-ray.)
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